generic glp-1 agonist FDA Approves First Weight Loss Drug FDA Approves Generic Version of
Description
DPP-4 inhibitors are body weight neutral and they are generally tolerated well without side effects (see also corresponding section below) (12, 19, 21, 22)

PD clinical trials The neuroprotective effects of GLP-1RAs, particularly exenatide, seem to be more promising in PD

Automated molecular microscopy: the new Leginon system
Fyfe JJ, Hamilton DL, Daly RM

Aronne LJ, Sattar N, Horn DB, et al

You should not take them if you have type 1 diabetes, diabetic ketoacidosis, or a history of pancreatitis